PCSK9 Gene Knockout (Verve Therapeutics) — Gene Therapy & Genetic Interventions
In vivo base editing to permanently inactivate PCSK9 gene for lifelong LDL cholesterol reduction.
Overview
Verve Therapeutics' VERVE-101/102 uses lipid nanoparticle (LNP)-delivered base editing to permanently inactivate the PCSK9 gene in hepatocytes, mimicking the naturally occurring PCSK9 loss-of-function mutations found in individuals with lifelong low LDL cholesterol and 88% reduced coronary heart disease risk. Phase 1b (heart-1) trial data showed 55% reduction in blood PCSK9 and 39-55% LDL-C reduction from a single infusion. This approach could replace lifelong statin or PCSK9 inhibitor therapy. Note: CRISPR-based gene therapy (Casgevy) is FDA-approved for sickle cell disease but not for PCSK9 editing.
Indications
- Heterozygous familial hypercholesterolemia (HeFH)
- Atherosclerotic cardiovascular disease (ASCVD)
- Statin-intolerant patients requiring LDL lowering
- PCSK9-driven hyperlipidemia
Mechanism of Action
GalNAc-conjugated lipid nanoparticles deliver ABE mRNA and guide RNA specifically to hepatocytes via ASGPR
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| VERVE-102 (LNP-ABE) | 0.1-0.6 mg/kg | Single IV infusion | Phase 1b dose-escalation; GalNAc-LNP for hepatocyte targeting |
Safety & Contraindications
- Off-target editing potential assessed by whole-genome sequencing
- Liver-targeted delivery limits systemic exposure but requires monitoring of hepatotoxicity
- One patient death in heart-1 trial (attributed to pre-existing severe cardiovascular disease, not treatment)
- Long-term durability and reversibility unknown
- Anti-Cas9 immune responses may limit re-dosing
- Currently enrolling Phase 1b clinical trial